rethinkTHC Search
Menu
Study breakdown

Review warns cannabis exposure in autistic individuals may increase psychosis risk through epigenetic mechanisms

ReviewPreliminary evidence
The takeaway

Autism spectrum individuals may be particularly vulnerable to cannabis-induced psychosis due to epigenetic effects on shared genetic pathways, with potential intergenerational consequences.

Clinicians working with autistic patients, families, researchers studying cannabis-psychosis links, and policymakers.

Autism genes carry epigenetic markings vulnerable to cannabinoid disruption

What the researchers found

Cannabis exposure in autistic individuals may exert disruptive epigenetic effects on brain regions critical to schizophrenia pathophysiology. Autism candidate genes carry bivalent chromatin markings that make them more vulnerable to cannabinoid-induced disruption. These epigenetic changes could potentially be inherited intergenerationally, supporting a developmental trajectory between autism and psychosis modulated by the endocannabinoid system.

Why it matters

As cannabis use becomes more common, including among autistic individuals seeking symptom relief, understanding population-specific risks is crucial, especially when those risks may extend to future generations.

The numbers in context

The review does not provide specific prevalence numbers but identifies autism candidate genes with bivalent chromatin markings as a molecular vulnerability.

How the study worked

Narrative review synthesizing evidence on cannabinoid-induced epigenetic effects in autism spectrum individuals, focusing on shared genetic pathways between autism and psychosis and the role of the endocannabinoid system.

What this study cannot tell us

Much of the evidence is from preclinical models. The proposed intergenerational epigenetic inheritance has limited direct evidence in humans. The review does not quantify the actual risk increase. Narrative rather than systematic review.

How to read the evidence

Narrative review drawing on preclinical and genetic evidence. The proposed mechanisms are plausible but largely unconfirmed in humans.

When this study was published

Published in 2022.

The bigger picture

The intersection of autism, cannabis, and psychosis risk represents an emerging area where genetic predisposition, epigenetic vulnerability, and substance exposure may converge, challenging one-size-fits-all approaches to cannabis policy.

Questions still open

  • What is the actual magnitude of psychosis risk for autistic cannabis users? Are there safe cannabinoid compounds (like CBD) for this population? How strong is the evidence for intergenerational epigenetic transmission?

Common questions

Are autistic people more vulnerable to cannabis-related psychosis?
This review presents evidence suggesting they may be, due to epigenetic vulnerabilities in autism-related genes that make them more susceptible to cannabinoid-induced disruption in brain areas involved in psychosis.
Could cannabis effects be passed to future generations?
The review suggests that cannabis-induced epigenetic changes in autistic individuals could theoretically be inherited, but this remains a hypothesis with limited direct human evidence.

Read the original research

Cannabis Use in Autism: Reasons for Concern about Risk for Psychosis.

Healthcare (Basel, Switzerland), 10(8)

Citation

Bortoletto, Riccardo; Colizzi, Marco. (2022). Cannabis Use in Autism: Reasons for Concern about Risk for Psychosis.. Healthcare (Basel, Switzerland), 10(8). https://doi.org/10.3390/healthcare10081553

Explore the wider topic